BioCorRx Extends Service Agreement with Dr. Balbir S. Brar as VP of Drug Development Following Pre-IND Meeting with the U.S. FDA

ANAHEIM, CA, Feb. 08, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTC: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that following the pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA), and based on the FDA’s responses to the Company’s development plan for BICX102, it has extended Dr. Balbir S. Brar’s agreement as VP of Drug Development for the BioCorRx Pharmaceuticals subsidiary for an additional one year period.

Brady Granier, President, CEO and Director, stated, “Dr. Brar’s guidance and expertise has been extremely valuable as we move forward with our plans for BICX102, a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders. We feel that his contributions to the briefing package which was submitted to the FDA played a huge role in what we believe was a very productive and successful meeting. We are very appreciative that he has agreed to continue with us on the next steps for BICX102.”

Dr. Brar, VP of Drug Development, commented, “The FDA meeting was a very positive next step for the company as we seek to commercialize our sustained release naltrexone implant.  This product addresses a multi-billion dollar, underserved market with few viable options for patients. I look forward to helping further advance and accelerate the regulatory approval process for this life saving product.”

Dr. Brar has over 25 years of experience in drug and device development, including worldwide regulatory submissions for over 50 INDs, 510(k)s and 505(b)(2)s, as well as approval of 8 NDAs for drugs currently on the market. Dr. Brar’s experience includes working with major pharmaceutical companies such as Lederle/Wyeth, where he was instrumental in the development of Azmacort for asthma, as well as topical Aristocort. At GlaxoSmithKline, as Director of Drug Safety, Dr. Brar participated in the development of Tazarotene. At Allergan, as VP of Drug Safety, he made major contributions towards the development, regulatory submission, and approval of Botox, Alphagan, Lumigan, Restasis, Ofloxacin, Azelex, and Avage.

For the past 10 years Dr. Brar has played a leadership role for several early stage biotechnology companies in the fields of nephropathy, oncology, ophthalmology, dermatology, pain, and cardiology. During this time, Dr. Brar served on the Board of Directors, and acted as President, EVP R&D, and Chief Technology Officer. Dr. Brar has a Ph.D. in Toxicology/Pathology from Rutgers University and D.V.M. from a university in India with finance training from Harvard Business School.

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of the use of sustained release naltrexone, usually in implantable form and under the direction and care of an independent licensed physician. Implant forms of naltrexone deliver the non-addictive medicine which is an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids, as well as some of their effects. The second component of the program developed by BioCorRx Inc. is a proprietary cognitive behavioral therapy (CBT) program specifically tailored for the treatment of alcohol and opioid use disorders for those receiving sustain release naltrexone treatment. The behavioral portion of the program also includes overlapping peer recovery support and tracking. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit

Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.


Contact Data